Find Us

GeneMed 2017

Baltimore, February 22-24, 2017

Rheonix is pleased to announce that Richard Montagna, Ph.D., FACB, Senior Vice President for Scientific and Clinical Affairs at Rheonix, has accepted an invitation to speak at GeneMed 2017. The abstract for his talk, titled “An Automated, Multipurpose Platform for Genetic Analysis” is available below.


Rheonix has developed a versatile, microfluidic platform with applications in multiple fields. Originally designed to automatically perform all aspects of molecular testing, many other applications have been implemented to meet the growing demands of the field (1-4). The original system was designed to automatically perform cell lysis, nucleic acid purification, multiplex PCR, detection and readout without any user intervention, starting with a broad spectrum of sample types, including whole blood, serum, plasma, urine, a variety of swabs (buccal, vaginal, endocervical, etc.) and fresh as well as formalin-fixed paraffin-embedded specimens. The system is capable of performing a variety of different assays including detection of single nucleotide polymorphisms, biomarkers associated with drug sensitivities, infectious disease markers, and oncology markers. Depending upon the specific test, the time to results of the fully automated assays ranges from 3 to 5.5 hours. Recently the system has been used to reduce the time of preparing Next Generation Sequencing (NGS) libraries from 1-2 days to less than 4 hours. Starting with raw specimens, NGS libraries were generated on the Rheonix system that were indistinguishable from libraries prepared from the same specimens using standard manual processes. Finally, under NIH-sponsored programs, the system has been further expanded to simultaneously perform both an immunoassay and a molecular assay from the same specimen. Thus far, assays for both HIV and ZIKA virus have been reduced to practice. The presentation will provide considerable data substantiating the Rheonix system’s capability to automate a broad spectrum of assay types without any user intervention.


  1. Spizz G, et al. “Rheonix CARD® Technology: An Innovative and Fully Automated Molecular Diagnostic Device,” Point of Care: The Journal of Near-Patient Testing & Technology, 11: 42-51 (2012).
  2. Spizz G, et al. “Determination of Genotypes Using A Fully Automated Molecular Detection System,” Arch Path Lab Med, 139: 805-811 (2015).
  3. Chen Z, et al. “A Rapid, Self-Confirming Assay for HIV: Simultaneous Detection of Anti-HIV Antibodies and Viral RNA, J. AIDS & Clin Res 540: (2016).
  4. Yasmin R, et al. “A Modifiable Microarray-Based Universal Sensor: Providing Sample-to-Results Automation,” Heliyon, DOI:10.1016/j.heliyon.2016.e00179 (2016).


About GeneMed:

Genome analysis is rapidly becoming an important tool in biomedical research for study of Future Medicine and health. Focusing on the scope of Genomic Medicine, the United Scientific Group is organizing this conference to gather top global researchers, leaders and innovators to announce new discoveries and cutting edge breakthroughs.

AMP 2016 Annual Meeting

Charlotte, November 10-12, 2016

Richard Montagna, Ph.D., FACB, Senior Vice President for Scientific and Clinical Affairs at Rheonix, will deliver a session, titled “Rheonix Encompass Optimum: The Road to Easier Assay Development,” on the AMP exhibit floor on Thursday, Nov. 10, from 3:00-3:45 p.m.

Attendees are invited to attend Dr. Montagna’s product showcase at 3:00 p.m. on Nov. 10, and visit Booth 1124 to meet the Rheonix team and learn more about how their microfluidic molecular analytical solutions can be used to improve efficiencies in laboratories.

About AMP:

Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing.